Weekly Investment Analysts’ Ratings Changes for Natera (NTRA)

Natera (NASDAQ: NTRA) recently received a number of ratings updates from brokerages and research firms:

• 12/15/2025 – Natera had its price target raised by analysts at Wells Fargo & Company from $190.00 to $205.00. They now have an “equal weight” rating on the stock.
• 12/15/2025 – Natera had its price target raised by analysts at Barclays PLC from $230.00 to $270.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Natera had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $260.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Natera had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $250.00 price target on the stock.
• 12/5/2025 – Natera had its price target raised by analysts at BTIG Research from $230.00 to $260.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Natera had its price target raised by analysts at Morgan Stanley from $220.00 to $265.00. They now have an “overweight” rating on the stock.
• 11/25/2025 – Natera had its price target raised by analysts at JPMorgan Chase & Co. from $240.00 to $250.00. They now have an “overweight” rating on the stock.
• 11/18/2025 – Natera had its price target raised by analysts at UBS Group AG from $218.00 to $280.00. They now have a “buy” rating on the stock.
• 11/13/2025 – Natera had its price target raised by analysts at Stephens from $197.00 to $235.00. They now have an “overweight” rating on the stock.
• 11/11/2025 – Natera had its price target raised by analysts at Morgan Stanley from $195.00 to $220.00. They now have an “overweight” rating on the stock.
• 11/11/2025 – Natera had its price target raised by analysts at Piper Sandler from $220.00 to $230.00. They now have an “overweight” rating on the stock.
• 11/7/2025 – Natera had its price target raised by analysts at Canaccord Genuity Group Inc. from $200.00 to $250.00. They now have a “buy” rating on the stock.
• 11/7/2025 – Natera had its price target raised by analysts at JPMorgan Chase & Co. from $210.00 to $240.00. They now have an “overweight” rating on the stock.
• 11/7/2025 – Natera had its price target raised by analysts at Wells Fargo & Company from $175.00 to $190.00. They now have an “equal weight” rating on the stock.
• 11/7/2025 – Natera had its price target raised by analysts at Barclays PLC from $210.00 to $230.00. They now have an “overweight” rating on the stock.
• 11/7/2025 – Natera had its price target raised by analysts at Evercore ISI from $190.00 to $250.00. They now have an “outperform” rating on the stock.
• 11/7/2025 – Natera had its price target raised by analysts at BTIG Research from $210.00 to $230.00. They now have a “buy” rating on the stock.
• 10/27/2025 – Natera was upgraded by analysts at BNP Paribas to a “hold” rating. They now have a $172.00 price target on the stock.
• 10/27/2025 – Natera was upgraded by analysts at BNP Paribas Exane from an “underperform” rating to a “neutral” rating. They now have a $172.00 price target on the stock.
• 10/23/2025 – Natera had its price target raised by analysts at BTIG Research from $200.00 to $210.00. They now have a “buy” rating on the stock.
• 10/20/2025 – Natera was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.

Insider Transactions at Natera

In other news, Director Rowan E. Chapman sold 4,366 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $243.10, for a total transaction of $1,061,374.60. Following the transaction, the director owned 5,777 shares of the company’s stock, valued at $1,404,388.70. This represents a 43.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Roelof Botha sold 75,000 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $236.12, for a total value of $17,709,000.00. Following the completion of the sale, the director owned 1,154,198 shares in the company, valued at $272,529,231.76. This represents a 6.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 365,164 shares of company stock valued at $76,621,909. 5.63% of the stock is currently owned by insiders.

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.